Enzyvant Logo White Verticle

Patient Focused. Results Driven.

OUR MISSION

DEVELOP

Transformative therapies for rare diseases with high unmet needs.

PURSUE

Innovative partnerships that create new opportunities in the rare disease field.

DELIVER

On our commitment to the patients, families, and communities we serve.

OUR PIPELINE

Enzyvant Pipeline Graphic

RVT-802

Complete DiGeorge Anomaly

Children with complete DiGeorge Anomaly are born without a thymus gland, resulting in primary immunodeficiency. The disease is almost uniformly fatal within the first 24 months of life if untreated.

RVT-801

Farber Disease

Farber disease is an ultra-rare lysosomal storage disease caused by a mutation in both alleles of the ASAH1 gene, resulting in the deficiency of the lysosomal enzyme acid ceramidase.

April 3, 2019

Enzyvant today announced that its investigational regenerative treatment (RVT-802) in late-stage development for congenital athymia will be featured during a platform presentation, at a symposium, and in a poster session at the Clinical Immunology Society (CIS) 2019.

March 21, 2019

The FDA has granted Rare Pediatric Disease and Fast Track designations for RVT-801, an investigational enzyme replacement therapy.

February 21, 2019

Rachelle is a proven leader and operator with deep experience bringing valued medicines to market in complex, fast-moving business environments,

Contact us for more information.